Continuing Education Activity

Alteplase, a recombinant tissue plasminogen activator (tPA), is a potent thrombolytic agent approved by the US Food and Drug Administration for the treatment of acute ischemic stroke (within 3 hours of onset), ST-segment elevation myocardial infarction, massive pulmonary embolism with hemodynamic instability, and occluded IV catheters. Alteplase works by converting plasminogen to plasmin, promoting clot breakdown and restoring blood flow. Administration of alteplase is highly time-sensitive, particularly in ischemic stroke, and requires accurate weight-based dosing, careful patient selection, and close monitoring for complications such as bleeding.

This activity reviews the clinical indications, mechanism of action, administration strategies, and key adverse effects of alteplase, along with essential considerations such as contraindications, toxicity, and monitoring requirements to ensure its safe use. This activity also underscores the importance of understanding alteplase pharmacology to guide individualized care and tailor acute interventions to each patient’s specific needs. This activity provides clinicians with the knowledge and skills necessary to administer alteplase in a timely, appropriate, and well-monitored manner, enabling the delivery of high-quality, evidence-based, patient-centered thrombolytic care. Additionally, this activity highlights the importance of interprofessional collaboration among healthcare providers in the safe and effective use of alteplase, particularly in managing acute ischemic stroke and other thromboembolic emergencies. By promoting accurate patient selection, weight-based individualized dosing, and vigilant monitoring, it supports the prevention of complications and enhances patient safety, ultimately improving recovery and clinical outcomes in eligible patients. 

Objectives:

• Identify appropriate indications and contraindications for alteplase (tissue plasminogen activator therapy) in acute thromboembolic conditions, including ischemic stroke, STEMI, pulmonary embolism, and catheter occlusion.
• Implement evidence-based protocols for the timely administration and monitoring of tissue plasminogen activator therapy across approved clinical settings.
• Assess patients for signs of therapeutic effectiveness and complications during and after alteplase administration.
• Collaborate with interprofessional healthcare teams to ensure timely, coordinated care during thromboembolic emergencies, optimizing outcomes with tissue plasminogen activator therapy.

Indications

Tissue plasminogen activator (tPA) is an endogenous serine protease secreted by vascular endothelial cells that promotes fibrinolysis by converting plasminogen into plasmin—the primary enzyme responsible for fibrin degradation. Alteplase, a recombinant form of human tPA (rtPA), is a potent thrombolytic agent used in clinical practice.

FDA-Approved Indications

Alteplase is approved by the US Food and Drug Administration (FDA) for the treatment of several critical thrombotic conditions, as mentioned below.

• Acute massive pulmonary embolism with hemodynamic instability.[1]
• ST-segment elevation myocardial infarction (STEMI).[2]
• Acute ischemic stroke when administered within 3 hours of symptom onset.[3][4][5]
• A low-dose formulation of alteplase, supplied as a 2 mg lyophilized powder for immediate reconstitution, is indicated to restore function in occluded central venous access devices.[6]

According to the 2025 American Heart Association (AHA) and American College of Cardiology (ACC) guidelines, patients presenting with STEMI at hospitals without percutaneous coronary intervention (PCI) capability should be transferred for primary PCI if it can be performed within 120 minutes of first medical contact. However, when symptom onset is less than 12 hours and timely transfer is not feasible, fibrinolytic therapy (such as alteplase) should be administered to patients without contraindications. Early thrombolysis in this context is emphasized by the guidelines for its role in reducing the incidence of major adverse cardiovascular events (MACE).[7] 

The AHA and American Stroke Association guidelines recommend prompt intravenous (IV) administration of alteplase for eligible patients with acute ischemic stroke, highlighting that its effectiveness is highly time-dependent. Healthcare providers should be prepared to manage possible adverse effects such as bleeding and orolingual angioedema, which could block the airway. The risks and potential benefits of treatment should be carefully discussed with the patient during eligibility assessment. Blood glucose levels should be checked before administering alteplase because hypoglycemia and hyperglycemia can mimic stroke symptoms. IV alteplase is not indicated for nonvascular neurological conditions. A non-contrast computed tomography (NCCT) scan is recommended before thrombolysis to rule out intracranial hemorrhage.[8] Additionally, the CHEST guidelines recommend considering systemic thrombolytic therapy for patients with acute pulmonary embolism and associated hypotension (systolic blood pressure <90 mmHg), as long as the risk of bleeding is low.[9]

The Kidney Disease Outcomes Quality Initiative (KDOQI) for vascular access recommends intraluminal administration of a thrombolytic agent into each central venous catheter (CVC) port to restore function in cases of CVC dysfunction caused by thrombosis. Alteplase or urokinase combined with 4% citrate per catheter lumen is recommended for reestablishing blood flow in occluded catheters. Among available dosing strategies, alteplase 2 mg per port is preferred over 1 mg for greater efficacy. Alteplase may be administered using either the dwell or push technique to manage catheter dysfunction.[10]

Off-Label Uses

In addition to its FDA-approved indications, alteplase is used off-label in several clinical scenarios where thrombolytic therapy may offer benefit.

• Treatment of deep vein thrombosis (DVT) and peripheral arterial thrombosis using catheter-directed thrombolysis with locally administered thrombolytic agents.[11][12]
• Ischemic stroke when alteplase is administered between 3 and 4.5 hours after symptom onset.
• Management of prosthetic valve thrombosis.[13]
• Adjunct treatment for pediatric pleural effusion or empyema.[14][15]
• Mild posterior ischemic circulation stroke occurring 4.5 to 24 hours after symptom onset.[16]
• Central retinal artery occlusion.[17][18]

Mechanism of Action

Alteplase functions within the endogenous fibrinolytic cascade by converting plasminogen to plasmin through hydrolysis of the arginine-valine bond in plasminogen. The activated plasmin subsequently degrades fibrin and fibrinogen, resulting in clot dissolution and the restoration of blood flow.[19][20] Notably, "tPA" refers to the endogenous tPA enzyme, not a specific therapeutic agent. Alteplase is the approved therapeutic agent, which is a recombinant, genetically modified form of tPA, also known as recombinant tissue-type plasminogen activator (rtPA).[21][22][23]

Pharmacokinetics

Absorption: Alteplase is administered via the IV route, resulting in immediate and complete systemic availability.

Distribution: The initial volume of distribution is approximately equal to the plasma volume.

Metabolism: Alteplase is primarily cleared through hepatic metabolism.

Excretion: Alteplase is rapidly cleared from the plasma, with an initial half-life of less than 5 minutes.

Administration

Available Dosage Forms and Strengths

Alteplase is available as a 2 mg lyophilized powder for catheter clearance. For systemic thrombolysis, it is supplied in single-dose vials of 50 mg and 100 mg lyophilized powder, each accompanied by 50 mL or 100 mL of sterile water for reconstitution.

Adult Dosage ( FDA-Approved Indications)

Pulmonary embolism: An alteplase dose of 100 mg should be administered over 2 hours, typically as a 10 mg bolus followed by a 90 mg infusion over 2 hours.

Ischemic stroke: Prompt evaluation and treatment are critical when administering alteplase for acute ischemic stroke.

• Before initiating therapy, a non-contrast CT (NCCT) scan should be obtained to rule out intracranial hemorrhage, and vital signs must be stabilized. Before administering tPA, a blood glucose test is required.[24] If the patient is on anticoagulation therapy, such as warfarin, prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) should be measured. The effectiveness of tPA is highly time-dependent; earlier administration is associated with better outcomes. 
• The maximum recommended dose of alteplase for ischemic stroke is 90 mg. 

  • For patients with a body weight of 100 kilograms or less, the recommended regimen is 0.09 mg/kg (10% of the total 0.9 mg/kg dose) administered as an IV bolus over 1 minute, followed by 0.81 mg/kg (90% of the 0.9 mg/kg dose) as a continuous infusion over 60 minutes.
  • For patients with a body weight of 100 kilograms or more, a fixed dose of 9 mg (10% of 90 mg) is given as an IV bolus over 1 minute, followed by 81 mg (90% of 90 mg) as a continuous infusion over 60 minutes.

ST-segment elevation myocardial infarction: For the treatment of STEMI, alteplase should be administered as soon as possible, ideally within 30 minutes of hospital arrival. Dosage is based on the patient's weight, as mentioned below.

• Adults with a body weight of 67 kg or more should receive a total dosage of 100 mg as follows: 15 mg IV bolus, followed by 50 mg IV infusion over 30 minutes, then 35 mg IV infusion over the next 60 minutes.
• Adults with a body weight of 67 kg or less should receive a 15 mg IV bolus, followed by an IV infusion of 0.75 mg/kg IV (not to exceed 50 mg) over 30 minutes, and then 0.5 mg/kg IV (not to exceed 35 mg) over the next 60 minutes.

Intravenous catheter occlusion: Alteplase (2 mg) should be instilled into the occluded lumen, followed by a 2-hour dwell time. This dosage may be repeated once if the initial attempt is unsuccessful. The use of alteplase in doses exceeding 4 mg for this indication has not been studied.

Adult Dosage (Off-Label Indications)

Catheter-directed therapy: Alteplase may be administered at a dose of 0.1 mg/kg/h, not to exceed 20 mg per 24 hours, for a duration of up to 96 hours.

Prosthetic valve thrombosis: Alteplase may be administered at a dose of 25 mg intravenously over 25 hours, repeated as necessary until a total dose of 200 mg is reached or resolution is confirmed by transesophageal echocardiography.

Alteplase is typically administered via the IV route as a bolus injection or continuous infusion. In emergency situations, intraosseous access may be used as an alternative route of administration.

Pediatric Dosage (Off-Label Indications)

Pediatric pleural effusions: A dose of 4 mg of alteplase diluted in 30 to 50 mL of 0.9% sodium chloride solution may be administered intrapleurally via chest tube. The solution is allowed to dwell for 1 hour and may be given as a single dose or as multiple doses at 24-hour intervals.

Specific Patient Populations

Hepatic impairment: No specific dosage adjustments have been established for patients with hepatic impairment. However, as alteplase is primarily cleared by the liver, impaired hepatic function may reduce its clearance, leading to increased systemic exposure. Close clinical monitoring is recommended in these patients.

Renal impairment: Alteplase is not primarily eliminated via the kidneys; therefore, no dosage adjustment is necessary for patients with renal impairment. 

Pregnancy considerations: Data on the use of alteplase in pregnant women are insufficient to determine the risk of drug-associated adverse developmental outcomes. Animal studies have shown embryocidal effects. Alteplase should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. Additionally, pregnancy may increase the risk of bleeding complications associated with thrombolytic therapy. 

Breastfeeding considerations: tPA is naturally present in human colostrum and breast milk, with the highest levels observed during the early stages of lactation. Due to its significant molecular weight and probable degradation in the infant’s gastrointestinal tract, systemic absorption of alteplase by the infant is unlikely. However, clinical data on the use of alteplase during breastfeeding are limited. Caution is advised, particularly for newborns and preterm infants.[25] A risk-benefit assessment should guide decisions on whether to continue breastfeeding.

Pediatric patients: The safety and effectiveness of systemic alteplase use in pediatric patients have not been established, and it is not FDA-approved for this indication. However, the FDA has approved low-dose alteplase for the treatment of CVC occlusions in pediatric patients.

Older patients: Advanced age should be considered in the risk-benefit assessment, but is not a contraindication to therapy. Although older patients, particularly those aged 80 or older, experience less favorable outcomes, higher mortality rates, and an increased incidence of intracranial hemorrhage compared to younger patients, intravenous alteplase still provides a greater likelihood of achieving independence at 3 months across all age groups.[26]

Adverse Effects

The most frequent severe adverse events associated with the administration of tPA are related to bleeding.[27][28][29]

Bleeding associated with alteplase therapy can be broadly categorized into 2 categories—internal and superficial.

• Internal bleeding includes intracranial bleeding (ranging from 0.4% to 15.4%), retroperitoneal bleeding (<1%), gastrointestinal bleeding (5%), genitourinary bleeding (4%), and respiratory bleeding.
• Superficial or surface bleeding primarily occurs at invaded or disturbed sites of tissue disruption, such as venous cutdowns, arterial punctures, and recent surgical wounds.
• Less serious spontaneous bleeding events may include ecchymosis (1%), gingival bleeding (<1%), and epistaxis (<1%).

In clinical studies involving adult patients with acute ischemic stroke (n=624), the incidence of intracranial bleeding—particularly symptomatic intracranial hemorrhage—was significantly higher in patients treated with alteplase compared to those receiving placebo (total intracranial bleeding: 15.4% versus 6.4%, P<.01; symptomatic intracranial bleeding: 8% versus 1.3%, P<.01). Despite this increased risk, there was no corresponding rise in 90-day mortality or severe disability among patients treated with alteplase. Studies indicate that the incidence of intracranial bleeding is dose-dependent, with the highest incidence observed at a dose of 150 mg (1.3%) compared to 100 mg (0.4%). Overall, the rate of adverse events, including bleeding, appears to correlate with the total cumulative exposure to tPA.

Cardiac dysrhythmias may occur during tPA administration for non-STEMI and are typically related to the restoration of tissue perfusion rather than direct drug effects.

Allergic reactions, including anaphylactic-type responses, may occur following exposure to tPA. The antigenicity of tPA can vary depending on its source. The rapid conversion of plasminogen to plasmin can trigger the complement cascade, leading to mast cell degranulation and, subsequently, an anaphylactic reaction.

Drug-Drug Interactions

Heparin: Heparin is commonly coadministered with alteplase, particularly in the treatment of STEMI and massive pulmonary embolism. Although this combination may enhance thrombolytic efficacy, it also significantly increases the risk of bleeding, including delayed hemorrhage. Heparin should be administered as a carefully titrated continuous infusion, with close monitoring of coagulation parameters such as activated partial thromboplastin time (aPTT). In the setting of acute ischemic stroke, heparin is typically withheld for at least 24 hours following alteplase administration unless there is a specific clinical indication.

P2Y12 inhibitors: P2Y12 inhibitors (such as clopidogrel, prasugrel, and ticagrelor) may be initiated after alteplase administration for myocardial infarction or as part of secondary stroke prevention following thrombolysis. However, concurrent use during or immediately after alteplase infusion is generally avoided due to the increased risk of bleeding. In stroke patients, delayed initiation—typically 24 hours or more after alteplase administration—may be considered once follow-up neuroimaging confirms the absence of intracranial hemorrhage.

Oral anticoagulants: Therapeutic anticoagulation with warfarin (INR >1.7) or recent use of direct oral anticoagulants (such as apixaban, rivaroxaban, and dabigatran) is a contraindication to alteplase administration in ischemic stroke due to the increased risk of intracranial hemorrhage. In cases of acute myocardial infarction or pulmonary embolism, treatment decisions should be guided by the patient’s coagulation status and the timing of the last anticoagulant dose. Co-administration of alteplase and oral anticoagulants should occur only with careful monitoring and an individualized assessment of the bleeding risk versus the therapeutic benefit.

Glycoprotein IIb/IIIa inhibitors: These potent antiplatelet agents (such as abciximab, eptifibatide, and tirofiban) significantly increase the risk of bleeding when used in conjunction with alteplase. Their use may be considered in selected high-risk PCI settings under close hemostatic monitoring.

Nonsteroidal anti-inflammatory drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit platelet aggregation and may increase the risk of bleeding when used concurrently with alteplase. Although not an absolute contraindication, their use should be avoided during the peri-thrombolytic period unless clinically necessary.

Other fibrinolytics: Sequential or combined use of alteplase with other fibrinolytic agents (such as streptokinase, tenecteplase, reteplase, and urokinase) is contraindicated due to additive fibrinolytic effects and an increased risk of severe bleeding and hemorrhagic stroke. Alteplase should not be administered within 24 hours of treatment with another fibrinolytic.

Aspirin: Low-dose aspirin is a component of standard dual antiplatelet therapy in patients with acute coronary syndrome and may be administered before or shortly after alteplase administration. Although it can enhance thrombolytic efficacy, concurrent use increases the risk of gastrointestinal and intracranial bleeding.[30] In the setting of ischemic stroke, aspirin is generally withheld for 24 hours following alteplase administration unless specifically indicated.

Contraindications

In 2016, the AHA published updated guidelines outlining the inclusion and exclusion criteria for the use of tPA in the management of ischemic stroke.[26] The list below includes the most recent absolute and relative contraindications for therapy, as determined by the AHA.

Absolute Contraindications

• Significant head trauma or prior stroke within the past 3 months
• Clinical presentation suggestive of subarachnoid hemorrhage
• Arterial puncture at a non-compressible site within the past 7 days
• History of intracranial hemorrhage
• Presence of an intracranial neoplasm, arteriovenous malformation, or aneurysm
• Recent intracranial or intraspinal surgery
• Elevated blood pressure (systolic >185 mmHg or diastolic >110 mmHg)
• Active internal bleeding
• Acute bleeding diathesis, including but not limited to:

  • Platelet count less than 100,000/mm³
  • Heparin use within the past 48 hours with an elevated aPTT above the upper limit of normal
  • Current use of anticoagulants with an INR greater than 1.7 or PT greater than 15 seconds
  • Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory parameters (eg, aPTT, INR, ecarin clotting time [ECT], thrombin time [TT], or specific anti–factor Xa activity assays)
  • Blood glucose concentration less than 50 mg/dL (2.7 mmol/L)
• CT demonstrates multilobar infarction (hypodensity involving more than one-third of a cerebral hemisphere)
• In cases of STEMI or pulmonary embolism, a recent history of stroke is a contraindication to TPA therapy [7]

Relative Contraindications

Recent evidence indicates that, in select cases and with careful evaluation of the risk-to-benefit ratio, fibrinolytic therapy may be administered despite the presence of one or more relative contraindications. The risks and benefits of IV rtPA administration should be thoroughly assessed when any of the following relative contraindications apply:

• Only minor or rapidly improving stroke symptoms (resolving spontaneously)
• Pregnancy
• Seizure at onset with postictal residual neurological impairments [31]
• Major surgery or severe trauma within the past 14 days
• Recent gastrointestinal or urinary tract hemorrhage (within the previous 21 days)
• Recent acute myocardial infarction (within the preceding 3 months)

Warning and Precautions 

Cholesterol embolization: Cholesterol embolism has been infrequently reported in patients receiving thrombolytic agents, and its actual incidence remains unknown. Clinical manifestations may include livedo reticularis (commonly referred to as "purple toe" syndrome) and acute kidney injury.[32][33][34]

Monitoring

No specific therapeutic drug monitoring guidelines exist for assessing the efficacy of tPA. When prolonged off-label therapy is necessary—such as with catheter-directed treatment or repeated dosing for valve thrombosis—serial imaging of the thrombus is appropriate. Safety monitoring should include PT, PTT, hemoglobin, and hematocrit to evaluate for ongoing bleeding. Fibrinogen levels below 150 mg/dL may indicate an increased risk of bleeding.

In STEMI, reperfusion is assessed using the Thrombolysis in Myocardial Infarction (TIMI) flow grade. For pulmonary embolism, therapeutic response is evaluated through measures such as right ventricular function, the right ventricle-to-left ventricle (RV/LV) ratio, and a reduction in pulmonary artery systolic pressure.[35] In ischemic stroke, the National Institutes of Health Stroke Scale (NIHSS) is used to gauge neurological improvement following alteplase administration, whereas the Modified Rankin Scale (mRS) and Barthel Index (BI) are used to monitor long-term functional outcomes.[36]

Toxicity

Signs and Symptoms of Overdose

Alteplase overdose may manifest as significant internal or external bleeding, particularly at arterial or venous puncture sites. Intramuscular injections and unnecessary trauma should be avoided during therapy. If arterial access is required while alteplase is being infused, a compressible upper extremity vessel should be used, with firm pressure applied for at least 30 minutes, followed by close monitoring. The concomitant use of anticoagulants such as heparin and aspirin increases bleeding risk and requires close monitoring. Intracranial hemorrhage should be suspected in the presence of new-onset headache, nausea, or vomiting.[37] In acute ischemic stroke, inaccurate weight-based dosing, especially overdosing due to overestimated body weight, has been linked to a higher risk of intracranial hemorrhage and worse functional outcomes. These findings underscore the crucial importance of accurate weight measurement before administering alteplase.[38]

Management of Overdose

No specific reversal agent exists for the potentially severe bleeding associated with tPA therapy. Alteplase should be discontinued immediately upon recognition of overdose or major bleeding. Management strategies commonly include antifibrinolytic agents such as tranexamic acid or aminocaproic acid, although specific dosing guidelines have not been established. When fibrinogen levels fall below 150 mg/dL, administration of fresh frozen plasma or cryoprecipitate may offer additional benefit. Prompt use of cryoprecipitate is recommended, with close monitoring of fibrinogen levels throughout treatment.[37]

Enhancing Healthcare Team Outcomes

Thrombolytic agents have proven efficacy in the treatment of acute ischemic stroke, massive pulmonary embolism, and STEMI. Effective use of these agents requires healthcare professionals, including physicians, advanced practice providers, nurses, pharmacists, and radiologists, to possess a comprehensive understanding of the indications and contraindications relevant to their specialties. In acute ischemic stroke, neurologists lead the decision-making process for alteplase administration by integrating rapid imaging assessment with eligibility criteria. For pulmonary embolism with hemodynamic compromise, critical care physicians are responsible for guiding the use of alteplase. Advanced practice providers, including physician assistants and nurse practitioners, play a crucial role in implementing protocols and monitoring patients.

Effective thrombolytic therapy depends not only on timely administration but also on careful patient assessment to identify and rule out potential contraindications. Nurses are responsible for educating patients about the procedure and closely monitoring for bleeding complications. Pharmacists must stay informed about novel anticoagulants and assess for potential drug interactions with thrombolytic agents. Coordination, multidisciplinary collaboration, clear communication, and ongoing vigilance among all healthcare professionals are essential to prevent serious complications associated with thrombolytic therapy.[4][39]

Outcomes

Numerous clinical trials have evaluated the effectiveness of thrombolytic agents in patients with acute myocardial infarction, pulmonary embolism, acute ischemic limb, and embolic stroke. When used to treat acute myocardial infarction, ischemic stroke, and pulmonary embolism, these agents generally yield fair to good outcomes. The most significant limitation of thrombolytic therapy is the delay in patient arrival to the emergency department or delayed diagnosis. Despite this, thrombolytic drugs have saved many lives, are cost-effective, and contribute to reduced hospital stays.[40][41][28]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, D Florez I, Izcovich A, Nieuwlaat R, Ross S, J Schünemann H, Wiercioch W, Zhang Y, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13;4(19):4693-4738. [PMC free article: PMC7556153] [PubMed: 33007077]

2.

Long B, Brady WJ, Gottlieb M. Fibrinolytic uses in the emergency department: a narrative review. Am J Emerg Med. 2025 Mar;89:85-94. [PubMed: 39700884]

3.

Grossberg JA, Rebello LC, Haussen DC, Bouslama M, Bowen M, Barreira CM, Belagaje SR, Frankel MR, Nogueira RG. Beyond Large Vessel Occlusion Strokes: Distal Occlusion Thrombectomy. Stroke. 2018 Jul;49(7):1662-1668. [PubMed: 29915125]

4.

Benoit JL, Khatri P, Adeoye OM, Broderick JP, McMullan JT, Scheitz JF, Vagal AS, Eckman MH. Prehospital Triage of Acute Ischemic Stroke Patients to an Intravenous tPA-Ready versus Endovascular-Ready Hospital: A Decision Analysis. Prehosp Emerg Care. 2018 Nov-Dec;22(6):722-733. [PubMed: 29847193]

5.

Mac Grory B, Yaghi S. Updates in Stroke Treatment. R I Med J (2013). 2018 Mar 01;101(2):30-33. [PubMed: 29490322]

6.

Scott DM, Ling CY, MacQueen BC, Baer VL, Gerday E, Christensen RD. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system. J Perinatol. 2017 Mar;37(3):291-295. [PubMed: 27831547]

7.

Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS., Peer Review Committee Members. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025 Jun 10;85(22):2135-2237. [PubMed: 40013746]

8.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. [PubMed: 31662037]

9.

Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Dec;160(6):2247-2259. [PubMed: 34352279]

10.

Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, Allon M, Asif A, Astor BC, Glickman MH, Graham J, Moist LM, Rajan DK, Roberts C, Vachharajani TJ, Valentini RP., National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020 Apr;75(4 Suppl 2):S1-S164. [PubMed: 32778223]

11.

Gong M, He X, Song J, Zhao B, Shi W, Chen G, Gu J. Catheter-Directed Thrombolysis With a Continuous Infusion of Low-Dose Alteplase for Subacute Proximal Venous Thrombosis: Efficacy and Safety Compared to Urokinase. Clin Appl Thromb Hemost. 2018 Nov;24(8):1333-1339. [PMC free article: PMC6714763] [PubMed: 29768935]

12.

Chopard R, Ecarnot F, Meneveau N. Catheter-directed therapy for acute pulmonary embolism: navigating gaps in the evidence. Eur Heart J Suppl. 2019 Nov;21(Suppl I):I23-I30. [PMC free article: PMC6868391] [PubMed: 31777454]

13.

Mashali MH, Ahmad Z, Omar Galal M, Al-Kouatli A. Effectiveness of alteplase infusion for the management of prosthetic mitral valve thrombosis in paediatric age group and proposed algorithm. Cardiol Young. 2023 May;33(5):747-753. [PubMed: 35656568]

14.

Generali JA, Cada DJ. Alteplase: pleural effusion (parapneumonic) and empyema in children. Hosp Pharm. 2013 Dec;48(11):912-21. [PMC free article: PMC3875108] [PubMed: 24474831]

15.

Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, Fashjian M, Cheng G, Ochoa S, Alape D, Folch E. Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection. A Single-Center Experience. Ann Am Thorac Soc. 2016 Sep;13(9):1512-8. [PubMed: 27333122]

16.

Yan S, Zhou Y, Lansberg MG, Liebeskind DS, Yuan C, Yu H, Chen F, Chen H, Zhang B, Mao L, Zhang X, Wang X, Zhang X, Chen Y, Zhou H, Zhong W, He Y, Chen K, Wang J, Chen H, Huang Y, Campbell BCV, Lou M., EXPECTS Group. Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours. N Engl J Med. 2025 Apr 03;392(13):1288-1296. [PubMed: 40174223]

17.

Tanaka S, Hayakawa M, Tasaki K, Ono R, Hirata K, Hosoo H, Ito Y, Marushima A, Yamagami H, Oshika T, Matsumaru Y. Successful recovery of vision following intravenous thrombolysis using low-dose alteplase in central retinal artery occlusion. Am J Emerg Med. 2025 Jan;87:216.e5-216.e9. [PubMed: 39542820]

18.

Subah G, Xu P, Zeller S, Nolan B, Lui A, Fortunato M, Feldstein E, Kafina M, Schloss ER, Elefant D, Chong J, Gandhi C, Al-Mufti F. Nationwide Incidence and Trends in Central Retinal Arterial Occlusion Management: A 5000-Patient Analysis. 2024 Jul-Aug 01Cardiol Rev. 32(4):291-296. [PubMed: 38666795]

19.

Imbarrato G, Bentley J, Gordhan A. Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers. J Neurosci Rural Pract. 2018 Apr-Jun;9(2):240-244. [PMC free article: PMC5912031] [PubMed: 29725176]

20.

Knecht T, Story J, Liu J, Davis W, Borlongan CV, Dela Peña IC. Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment. Int J Mol Sci. 2017 Dec 19;18(12) [PMC free article: PMC5751355] [PubMed: 29257093]

21.

Roth JM. Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke. Proc (Bayl Univ Med Cent). 2011 Jul;24(3):257-9. [PMC free article: PMC3124916] [PubMed: 21738304]

22.

Hutten EM, van de Ven AAJM, Mencke R, Pleijhuis RG. Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke. Stroke. 2024 Aug;55(8):2193-2197. [PubMed: 38939926]

23.

Majumder D. Ischemic Stroke: Pathophysiology and Evolving Treatment Approaches. Neurosci Insights. 2024;19:26331055241292600. [PMC free article: PMC11497522] [PubMed: 39444789]

24.

Wang Y, Jiang G, Zhang J, Wang J, You W, Zhu J. Blood glucose level affects prognosis of patients who received intravenous thrombolysis after acute ischemic stroke? A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1120779. [PMC free article: PMC10130663] [PubMed: 37124754]

25.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Dec 15, 2024. Alteplase. [PubMed: 29999667]

26.

Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE., American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Feb;47(2):581-641. [PubMed: 26696642]

27.

Liu H, Zheng H, Cao Y, Pan Y, Wang D, Zhang R, You S, Zhang X, Li S, Tong X, Liu CF, Wang Y. Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis. J Stroke Cerebrovasc Dis. 2018 Apr;27(4):988-997. [PubMed: 29224744]

28.

Gilliland C, Shah J, Martin JG, Miller MJ. Acute Limb Ischemia. Tech Vasc Interv Radiol. 2017 Dec;20(4):274-280. [PubMed: 29224661]

29.

Vivien D. Can the benefits of rtPA treatment for stroke be improved? Rev Neurol (Paris). 2017 Nov;173(9):566-571. [PubMed: 28797689]

30.

Peng TJ, Schwamm LH, Fonarow GC, Hassan AE, Hill M, Messé SR, Coronado F, Falcone GJ, Sharma R. Contemporary Prestroke Dual Antiplatelet Use and Symptomatic Intracerebral Hemorrhage Risk After Thrombolysis. JAMA Neurol. 2024 Jul 01;81(7):722-731. [PMC free article: PMC11106713] [PubMed: 38767894]

31.

Feher G, Gurdan Z, Gombos K, Koltai K, Pusch G, Tibold A, Szapary L. Early seizures after ischemic stroke: focus on thrombolysis. CNS Spectr. 2020 Feb;25(1):101-113. [PubMed: 30915936]

32.

Oe K, Araki T, Nakashima A, Sato K, Konno T, Yamagishi M. Late onset of cholesterol crystal embolism after thrombolysis for cerebral infarction. Intern Med. 2010;49(9):833-6. [PubMed: 20453403]

33.

Mooney T, Joseph P. Purple toes syndrome following stroke thrombolysis and warfarin therapy. Intern Med J. 2014 Jan;44(1):107-8. [PubMed: 24450530]

34.

Gupta BK, Spinowitz BS, Charytan C, Wahl SJ. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator. Am J Kidney Dis. 1993 Jun;21(6):659-62. [PubMed: 8503421]

35.

Li HY, Wang YB, Ren XY, Wang J, Wang HS, Jin YH. Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis. Pharmacology. 2023;108(2):111-126. [PMC free article: PMC10015747] [PubMed: 36603558]

36.

You S, Wang Y, Wang X, Maeda T, Ouyang M, Han Q, Li Q, Song L, Zhao Y, Chen C, Delcourt C, Ren X, Carcel C, Zhou Z, Cao Y, Liu CF, Zheng D, Arima H, Robinson TG, Chen X, Lindley RI, Chalmers J, Anderson CS. Twenty-Four-Hour Post-Thrombolysis NIHSS Score As the Strongest Prognostic Predictor After Acute Ischemic Stroke: ENCHANTED Study. J Am Heart Assoc. 2024 Sep 17;13(18):e036109. [PMC free article: PMC11935628] [PubMed: 39258531]

37.

O'Carroll CB, Aguilar MI. Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications. Neurohospitalist. 2015 Jul;5(3):133-41. [PMC free article: PMC4530424] [PubMed: 26288671]

38.

Sahlas DJ, Gould L, Swartz RH, Mohammed N, McNicoll-Whiteman R, Naufal F, Oczkowski W. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes. J Stroke Cerebrovasc Dis. 2014 Jan;23(1):155-9. [PubMed: 23375748]

39.

Kepplinger J, Barlinn K, Deckert S, Scheibe M, Bodechtel U, Schmitt J. Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis. Neurology. 2016 Sep 27;87(13):1344-51. [PubMed: 27566746]

40.

Aoki J, Suzuki K, Suda S, Okubo S, Mishina M, Nishiyama Y, Sakamoto Y, Kimura K. In Hyperacute Recanalization Therapy, Early Hospital Arrival Improves Outcome in Patients with Large Artery Occlusion. Eur Neurol. 2018;79(5-6):335-341. [PubMed: 29986341]

41.

Man S, Zhao X, Uchino K, Hussain MS, Smith EE, Bhatt DL, Xian Y, Schwamm LH, Shah S, Khan Y, Fonarow GC. Comparison of Acute Ischemic Stroke Care and Outcomes Between Comprehensive Stroke Centers and Primary Stroke Centers in the United States. Circ Cardiovasc Qual Outcomes. 2018 Jun;11(6):e004512. [PMC free article: PMC5978771] [PubMed: 29794035]

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Pradeep Bollu declares no relevant financial relationships with ineligible companies.